# A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer

> **NCT05328908** · PHASE3 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 770 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** Nivolumab-relatlimab FDC
- **DRUG:** Regorafenib
- **DRUG:** TAS-102

## Key facts

- **NCT ID:** NCT05328908
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-28
- **Primary completion:** 2025-07-14
- **Final completion:** 2025-07-14
- **Target enrollment:** 770 (ACTUAL)
- **Why stopped:** Inability to meet protocol objectives
- **Last updated:** 2025-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05328908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05328908, "A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05328908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*